New drug ST101 takes on Hard-to-Treat cancers
NCT ID NCT04478279
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests an experimental drug called ST101 in people with advanced solid tumors that cannot be removed by surgery or have spread. The trial includes cancers like glioblastoma, melanoma, breast, and prostate cancer. It aims to find a safe dose and see if the drug can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ST101 (an experimental drug given intravenously)
What this could lead to
If it works, this could point toward a new treatment option for several hard-to-treat cancers like glioblastoma and metastatic melanoma.
What could go wrong
This is an early phase 1-2 trial with only 125 participants, so it is primarily testing safety and dosing. The drug may not shrink tumors or improve survival, and side effects are unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Columbia University
New York, New York, 10032, United States
-
Duke University School of Medicine
Durham, North Carolina, 27708, United States
-
Edinburgh Cancer Centre
Edinburgh, EH4 2SP, United Kingdom
-
Northwestern Medicine Cancer Centers
Warrenville, Illinois, 60555, United States
-
START Midwest
Grand Rapids, Michigan, 49503, United States
-
Sarah Cannon Research Institute
Denver, Colorado, 80218, United States
-
Sarah Cannon Research Institute
Nashville, Tennessee, 37203, United States
-
Sarah Cannon Research Institute UK
London, W1G 6AD, United Kingdom
-
The Beaston West of Scotland Cancer Centre
Glasgow, G12 0YN, United Kingdom
-
University of California, San Francisco
San Francisco, California, 94143, United States
-
University of Leeds
Leeds, LS9 7TF, United Kingdom